



BioAlliance Pharma announces participation in the SmallCap Event On April 27th and 28th in Paris

Paris, April 20th 2009 - BioAlliance Pharma SA (Euronext Paris - BIO), a specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, today announced that it will participate in the SmallCap Event, a forum dedicated to meetings between institutional investors and listed companies from the Euronext Zone, on Monday 27th and Tuesday 28th of April in Paris, Pullmann Hotel, Avenue de Suffren.

During these two days, Nicolas Fellmann, Chief Financial Officer will meet with institutional investors to present BioAlliance Pharma and its development strategy.

About BioAlliance Pharma

As a preferred partner for hospital-based specialists, BioAlliance Pharma is a specialty biopharmaceutical company which develops and markets innovative products, especially in the fields of opportunistic infections and chemotherapy complications. In areas where medical needs are insufficiently met, our targeted approaches help overcome drug resistance and improve patient health & quality of life. BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs.

For more information, visit the BioAlliance Pharma web site at <http://www.bioalliancepharma.com>.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2008 Reference Document filed with the AMF on April 7, 2009, which is available on the AMF website (<http://www.amf-france.org>) or on BioAlliance Pharma S.A.'s website (<http://www.bioalliancepharma.com>).

BioAlliance Pharma SA

Dominique Costantini, President and CEO
Tel.: +33 1 45 58 76 01 - dominique.costantini@bioalliancepharma.com
Nicolas Fellmann, CFO
Tel.: +33 1 45 58 71 00 - Nicolas.fellmann@bioalliancepharma.com

ALIZE RP

Caroline Carmagnol
Tel.: +33 6 64 18 99 59 - caroline@alizerp.com